Patent ID: 7947262

Claim:
A method of treating symptoms of an IgE-mediated mast cell or peripheral blood basophil allergic response in a patient in need thereof, comprising the step of administering to said patient a fullerene that is covalently modified to be water-soluble in an amount sufficient to alleviate said symptoms of said IgE-mediated mast cell or peripheral blood basophil allergic response, wherein said fullerene that is covalently modified to be water-soluble is a water soluble C 40 , C 50 , C 60 or C 70 fullerene modified by covalent attachment of one or more moieties selected from the group consisting of pyridine, hydroxyl, cyclodextrin, polyvinylpyrrolidone, bis(monosuccinimide, p,p′-bis(2-amino-ethyl)-diphenyl, polyamines, and N-ethyl polyamines; and wherein said IgE-mediated mast cell or peripheral blood basophil allergic response is selected from the group consisting of allergies, Type I hypersensitivity, anaphylaxis, and hay fever.